ANL 34.00 Increased By ▲ 0.90 (2.72%)
ASC 14.90 Increased By ▲ 0.55 (3.83%)
ASL 25.10 Increased By ▲ 0.62 (2.53%)
AVN 92.20 Decreased By ▼ -0.30 (-0.32%)
BOP 9.14 Increased By ▲ 0.08 (0.88%)
BYCO 9.85 Increased By ▲ 0.15 (1.55%)
DGKC 134.70 Increased By ▲ 2.51 (1.9%)
EPCL 50.62 Increased By ▲ 0.52 (1.04%)
FCCL 24.63 Increased By ▲ 0.33 (1.36%)
FFBL 25.86 Increased By ▲ 1.46 (5.98%)
FFL 15.49 Increased By ▲ 0.47 (3.13%)
HASCOL 10.56 No Change ▼ 0.00 (0%)
HUBC 86.33 Increased By ▲ 1.23 (1.45%)
HUMNL 7.02 Increased By ▲ 0.27 (4%)
JSCL 25.65 Increased By ▲ 0.40 (1.58%)
KAPCO 41.55 Increased By ▲ 2.80 (7.23%)
KEL 4.02 Increased By ▲ 0.04 (1.01%)
LOTCHEM 14.45 Increased By ▲ 0.02 (0.14%)
MLCF 46.42 Increased By ▲ 0.54 (1.18%)
PAEL 37.25 Increased By ▲ 0.55 (1.5%)
PIBTL 11.70 Increased By ▲ 0.27 (2.36%)
POWER 10.25 Increased By ▲ 0.10 (0.99%)
PPL 90.90 Increased By ▲ 1.20 (1.34%)
PRL 26.86 Increased By ▲ 0.61 (2.32%)
PTC 8.71 Increased By ▲ 0.11 (1.28%)
SILK 1.35 No Change ▼ 0.00 (0%)
SNGP 42.71 Increased By ▲ 1.31 (3.16%)
TRG 146.10 Increased By ▲ 3.00 (2.1%)
UNITY 30.20 Increased By ▲ 0.41 (1.38%)
WTL 1.41 Decreased By ▼ -0.01 (-0.7%)
BR100 4,965 Increased By ▲ 76.98 (1.57%)
BR30 25,754 Increased By ▲ 477.72 (1.89%)
KSE100 45,837 Increased By ▲ 558.82 (1.23%)
KSE30 19,174 Increased By ▲ 275.54 (1.46%)
Pakistan

Pakistani pharma in negotiation with Gilead to manufacture COVID-19 drug

BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesi
12 May 2020
  • BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries.

Pakistan pharmaceutical company Ferzsons Laboratories informed that its subsidiary BF Biosciences Ltd (BFBL) was in negotiations with Gilead Sciences Inc for the manufacture and sale of Remdesivir.

In its filing to the Pakistan Stock Exchange (PSX), Ferozsons informed that its listed subsidiary BF Biosciences Limited (BFBL) was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries. “There is no obligation at this time for any party to execute any transaction,” Ferozsons told the PSX.

“If an agreement is executed by Gilead and BFBL, once production starts, we are confident that we will have sufficient quantities over time to serve the needs of the patients in Pakistan,” the company added.

“However, at the moment we are uncertain as to the timelines for first launch as an agreement remains to be executed, and thereafter local regulatory approvals and sourcing of Active Pharmaceutical Ingredient for manufacturing Remdesivir may take some time.”

It may be mentioned here that Remdesivir has been approved by the US FDA for the treatment of COVID-19 treatment. “The optimal duration of treatment was under ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations have been suggested based on the severity of the disease.”